Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

An easier way to manipulate malaria genes

12.08.2014

New approach to knocking out parasite's genes could make it easier to identify drug targets

Plasmodium falciparum, the parasite that causes malaria, has proven notoriously resistant to scientists' efforts to study its genetics. It can take up to a year to determine the function of a single gene, which has slowed efforts to develop new, more targeted drugs and vaccines.

MIT biological engineers have now demonstrated that a new genome-editing technique, called CRISPR, can disrupt a single parasite gene with a success rate of up to 100 percent — in a matter of weeks. This approach could enable much more rapid gene analysis and boost drug-development efforts, says Jacquin Niles, an associate professor of biological engineering at MIT.

"Even though we've sequenced the entire genome of Plasmodium falciparum, half of it still remains functionally uncharacterized. That's about 2,500 genes that if only we knew what they did, we could think about novel therapeutics, whether it's drugs or vaccines," says Niles, the senior author of a paper describing the technique in the Aug. 10 online edition of Nature Methods.

The paper's lead author is Jeffrey Wagner, a recent PhD recipient and current MIT postdoc in biological engineering. Graduate student Randall Platt, recent PhD recipient Stephen Goldfless, and Feng Zhang, the W.M. Keck Career Development Assistant Professor in Biomedical Engineering, also contributed to the research.

Plasmodium falciparum, a blood-borne parasite carried by mosquitoes, is responsible for most of the estimated 219 million cases, and 655,000 deaths, from malaria per year. Treatments include chloroquine and artemisin, but the parasite is becoming more resistant to these drugs.

There is an urgent need to develop new drugs, but potential genetic targets are hard to identify. In animals such as mice, it is fairly routine to study gene functions by deleting a target gene or replacing it with an artificial piece of DNA. However, in Plasmodium falciparum, this approach can take up to a year because it relies on homologous recombination, a type of genetic swapping that cells use to repair broken DNA strands. This occurs very rarely in the genome of the malaria parasite.

"You have to rely on this really inefficient process that occurs only if you have spontaneous DNA strand breaks that happen to fall within your region of interest," Niles says.

Using this time-consuming approach, scientists have been able to identify functions for some of the genes necessary for the parasite to invade red blood cells, as well as some of the genes required for the parasite to later erupt from blood cells. More recently, researchers have successfully used enzymes called zinc finger nucleases to cut out specific genes, but this approach is costly because it requires a new nuclease to be designed for each gene target.

CRISPR, a gene-editing system devised within the past several years, exploits a set of bacterial proteins that protect microbes from viral infection. The system includes a DNA-cutting enzyme, Cas9, bound to a short RNA guide strand that is programmed to bind to a specific genome sequence, telling Cas9 where to make its cut. This approach allows scientists to target and delete any gene by simply changing the RNA guide strand sequence.

As soon as researchers successfully demonstrated that this system could work in cells other than bacteria, Niles started to think about using it to manipulate Plasmodium falciparum. To test this approach, he and his colleagues tried using CRISPR to disrupt two genes, kahrp and eba-175, that had previously been knocked out in malaria using traditional approaches.

The kahrp gene produces a protein that causes red blood cells, which are normally smooth, to develop a knobby appearance when infected with malaria. Niles' team was able to disrupt this gene in 100 percent of parasites treated with the CRISPR system; red blood cells infected by those parasites remained smooth.

With eba-175, which codes for a protein that binds to red blood cell receptors and helps the parasite get into the cells, the researchers disrupted this gene in 50 to 80 percent of parasites manipulated with the CRISPR system. "We consider this to be a win," Niles says. "Compared to the efficiency with which P. falciparum genetics have been done in the past, even 50 percent is pretty substantial."

For both targets, the researchers demonstrated that they could insert a gene for the protein luciferase, which emits light, in addition to turning off the existing genes.

Now that CRISPR technology has been validated in Plasmodium falciparum, Niles expects that many scientists will adopt it for genetic studies of the parasite. Such efforts could reveal more about how the parasite invades red blood cells and replicates inside cells, which could generate new drug and vaccine targets.

"I think the impact could be quite huge," Niles says. "It lowers the barrier to really being more imaginative in terms of how we do experiments and the kinds of questions that we can ask."

The research was funded by the National Institute of General Medical Sciences, the National Institute of Environmental Health Sciences, the National Science Foundation, the National Institutes of Health, and the Bill and Melinda Gates Foundation.

Abby Abazorius | Eurek Alert!
Further information:
http://www.mit.edu

Further reports about: CRISPR DNA MIT Massachusetts Plasmodium blood develop drugs falciparum genes parasite parasites technique

More articles from Life Sciences:

nachricht Gene switch may repair DNA and prevent cancer
12.02.2016 | Institute for Integrated Cell-Material Sciences at Kyoto University

nachricht New method opens crystal clear views of biomolecules
11.02.2016 | Deutsches Elektronen-Synchrotron DESY

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Production of an AIDS vaccine in algae

Today, plants and microorganisms are heavily used for the production of medicinal products. The production of biopharmaceuticals in plants, also referred to as “Molecular Pharming”, represents a continuously growing field of plant biotechnology. Preferred host organisms include yeast and crop plants, such as maize and potato – plants with high demands. With the help of a special algal strain, the research team of Prof. Ralph Bock at the Max Planck Institute of Molecular Plant Physiology in Potsdam strives to develop a more efficient and resource-saving system for the production of medicines and vaccines. They tested its practicality by synthesizing a component of a potential AIDS vaccine.

The use of plants and microorganisms to produce pharmaceuticals is nothing new. In 1982, bacteria were genetically modified to produce human insulin, a drug...

Im Focus: The most accurate optical single-ion clock worldwide

Atomic clock experts from the Physikalisch-Technische Bundesanstalt (PTB) are the first research group in the world to have built an optical single-ion clock which attains an accuracy which had only been predicted theoretically so far. Their optical ytterbium clock achieved a relative systematic measurement uncertainty of 3 E-18. The results have been published in the current issue of the scientific journal "Physical Review Letters".

Atomic clock experts from the Physikalisch-Technische Bundesanstalt (PTB) are the first research group in the world to have built an optical single-ion clock...

Im Focus: Goodbye ground control: autonomous nanosatellites

The University of Würzburg has two new space projects in the pipeline which are concerned with the observation of planets and autonomous fault correction aboard satellites. The German Federal Ministry of Economic Affairs and Energy funds the projects with around 1.6 million euros.

Detecting tornadoes that sweep across Mars. Discovering meteors that fall to Earth. Investigating strange lightning that flashes from Earth's atmosphere into...

Im Focus: Flow phenomena on solid surfaces: Physicists highlight key role played by boundary layer velocity

Physicists from Saarland University and the ESPCI in Paris have shown how liquids on solid surfaces can be made to slide over the surface a bit like a bobsleigh on ice. The key is to apply a coating at the boundary between the liquid and the surface that induces the liquid to slip. This results in an increase in the average flow velocity of the liquid and its throughput. This was demonstrated by studying the behaviour of droplets on surfaces with different coatings as they evolved into the equilibrium state. The results could prove useful in optimizing industrial processes, such as the extrusion of plastics.

The study has been published in the respected academic journal PNAS (Proceedings of the National Academy of Sciences of the United States of America).

Im Focus: New study: How stable is the West Antarctic Ice Sheet?

Exceeding critical temperature limits in the Southern Ocean may cause the collapse of ice sheets and a sharp rise in sea levels

A future warming of the Southern Ocean caused by rising greenhouse gas concentrations in the atmosphere may severely disrupt the stability of the West...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Symposium on Climate Change Adaptation in Africa 2016

12.02.2016 | Event News

Travel grants available: Meet the world’s most proficient mathematicians and computer scientists

09.02.2016 | Event News

AKL’16: Experience Laser Technology Live in Europe´s Largest Laser Application Center!

02.02.2016 | Event News

 
Latest News

LIGO confirms RIT's breakthrough prediction of gravitational waves

12.02.2016 | Physics and Astronomy

Gene switch may repair DNA and prevent cancer

12.02.2016 | Life Sciences

Using 'Pacemakers' in spinal cord injuries

12.02.2016 | Medical Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>